THE DEAL, AT A GLANCE
From the announcementRidge Bio
01What it does] Ridge Biotechnologies is a pioneering company focused on AI-enabled precision enzyme and targeted drug design.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Dimension Capital, founding investorsFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedRidge Bio raised $38M Seed, announced 2026-09-09From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersRidge Bio’s $38M seed positions it to develop AI-designed bioconjugate drugs focused on safer, more precise medicines, with Dimension Capital and founding investors…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Ridge Bio · Financing Record
Explore source-linked visual explanations for Ridge Bio. Unsupported claims are withheld while source review continues.
Record 12225 · Recorded date: 2026-09-09
What it does
The Ridge Bio platform uses proprietary machine learning models built on massive cell-free datasets to design precision enzymes and targeted delivery systems at unprecedented speed and scale.
Source: ridgebio.com ↗